

**CENTER FOR DRUG  
EVALUATION AND  
RESEARCH**

**APPLICATION NUMBER:**

**75-761**

**CHEMISTRY REVIEW(S)**

1. CHEMISTRY REVIEW NO. 1
2. ANDA 75-761
3. NAME AND ADDRESS OF APPLICANT  
American Pharmaceutical Partners, Inc.  
Attention: Michael Lisjak  
2045 North Cornell Avenue  
Melrose Park, IL 60160
4. BASIS OF SUBMISSION  
Cordarone Injection (50 mg/mL, 3 mL fill in a 3 mL vial)  
manufactured by Wyeth-Ayerst Company is the RLD. The  
expiration of Orphan Drug Exclusivity is on 08/03/02.
5. SUPPLEMENT(s)  
N/A
6. PROPRIETARY NAME  
N/A
7. NONPROPRIETARY NAME  
Amiodarone Hydrochloride
8. SUPPLEMENT(s) PROVIDE(s) FOR:  
N/A
9. AMENDMENTS AND OTHER DATES:  
December 23, 1999---Original Submission  
February 10, 2000--New Correspondence  
February 18, 2000--Acknowledgement receipt  
March 7, 2000--Labeling review unacceptable  
March 17, 2000--Bio waiver granted
10. PHARMACOLOGICAL CATEGORY  
Antiarrhythmic (class III)
11. Rx or OTC  
Rx
12. RELATED DMFs  

---
13. DOSAGE FORM  
Injection
14. POTENCY  
50 mg/mL in 3 cc vials
15. CHEMICAL NAME AND STRUCTURE  
(2-butyl-3-benzofuranyl) [4-(diethylamino)ethoxy]-3,5-  
diiodophenyl]methanone hydrochloride
16. RECORDS AND REPORTS  
None.

17. COMMENTS

The bacterial endotoxin specification will be consulted with micro since the RLD API has a specification of NMT \_\_\_\_\_ instead of the proposed NMT \_\_\_\_\_. The actual BE test result is LT \_\_\_\_\_ (p 134).

18. CONCLUSIONS AND RECOMMENDATIONS


Recommend not approvable letter to issue (Major).

19. REVIEWER:

Edwin Ramos

DATE COMPLETED:

April 30, 2000

 6/14/00

**APPEARS THIS WAY  
ON ORIGINAL**

**Redacted** 10

**Page(s) of trade**

**secret and /or**

**confidential**

**commercial**

**information**


There is no Chemistry Review #2.

It appears there was an error in the numbering sequence.

1. CHEMISTRY REVIEW NO. 3
2. ANDA 75-761
3. NAME AND ADDRESS OF APPLICANT  
 American Pharmaceutical Partners, Inc.  
 Attention: Michael Lisjak  
 2045 North Cornell Avenue  
 Melrose Park, IL 60160
4. BASIS OF SUBMISSION  
 Cordarone Injection (50 mg/mL, 3 mL fill in a 3 mL vial) manufactured by Wyeth-Ayerst Company is the RLD. The expiration of Orphan Drug Exclusivity is on 08/03/02. *20-377*
5. SUPPLEMENT(s)  
 N/A
6. PROPRIETARY NAME  
 N/A
7. NONPROPRIETARY NAME  
 Amiodarone Hydrochloride
8. SUPPLEMENT(s) PROVIDE(s) FOR:  
 N/A
9. AMENDMENTS AND OTHER DATES:  
 December 22, 1999- Original Submission  
 February 10, 2000- New Correspondence  
 February 18, 2000- Acknowledgement receipt  
 March 7, 2000- Labeling review unacceptable  
 March 17, 2000- Bio waiver granted  
 June 21, 2000- Deficiency letter (chem)  
 November 1, 2000- Deficiency letter (micro)  
 November 10, 2000- Amendment (chem & micro)  
 April 10, 2001- Deficiency (facsimile)  
 April 24, 2001- Telecom  
 April 24, 2001- New correspondence  
 May 4, 2001- Telecom amendment (chem)
10. PHARMACOLOGICAL CATEGORY  
 Antiarrhythmic (class III)
11. Rx or OTC  
 Rx
12. RELATED DMFs
13. DOSAGE FORM  
 Injection
14. POTENCY  
 50 mg/mL in 3 cc vials

Injection 50 mg/mL in 3 cc vials

- 15. CHEMICAL NAME AND STRUCTURE  
(2-butyl-3-benzofuranyl) [4-(diethylamino)ethoxy]-3,5-diodophenyl]methanone hydrochloride
- 16. RECORDS AND REPORTS  
None.
- 17. COMMENTS  
**The proposed bacterial finished drug product endotoxin specification of NMT  has been revised to NMT**
- 18. CONCLUSIONS AND RECOMMENDATIONS  
Recommend approvable letter to issue.
- 19. REVIEWER: DATE COMPLETED:  
Edwin Ramos May 9, 2001

 5/9/01

**APPEARS THIS WAY  
ON ORIGINAL**

**Redacted**     11    

**Page(s) of trade**

**secret and /or**

**confidential**

**commercial**

**information**

- ✓
1. CHEMISTRY REVIEW NO. 4
  2. ANDA 75-761
  3. NAME AND ADDRESS OF APPLICANT  
American Pharmaceutical Partners, Inc.  
Attention: Michael Lisjak  
2045 North Cornell Avenue  
Melrose Park, IL 60160
  4. BASIS OF SUBMISSION  
Cordarone Injection (50 mg/mL, 3 mL fill in a 3 mL vial)  
manufactured by Wyeth-Ayerst Company is the RLD. The expiration of  
Orphan Drug Exclusivity is on 08/03/02.
  5. SUPPLEMENT(s)  
N/A
  6. PROPRIETARY NAME  
N/A
  7. NONPROPRIETARY NAME  
Amiodarone Hydrochloride
  8. SUPPLEMENT(s) PROVIDE(s) FOR:  
N/A
  9. AMENDMENTS AND OTHER DATES:  
December 22, 1999- Original Submission  
February 10, 2000- New Correspondence  
February 18, 2000- Acknowledgement receipt  
March 7, 2000- Labeling review unacceptable  
March 17, 2000- Bio waiver granted  
June 21, 2000- Deficiency letter (chem)  
November 1, 2000- Deficiency letter (micro)  
November 10, 2000- Amendment (chem & micro)  
April 10, 2001- Deficiency (facsimile)  
April 24, 2001- Telecom  
April 24, 2001- New correspondence  
May 4, 2001- Telecom amendment (chem)  
August 23, 2001- TA letter  
May 21, 2002- Minor amendment  
July 2, 2002- Labeling amendment  
July 22, 2002- Labeling amendment
  10. PHARMACOLOGICAL CATEGORY  
Antiarrhythmic (class III)
  11. Rx or OTC  
Rx
  12. RELATED DMFs

13. DOSAGE FORM  
Injection
14. POTENCY  
50 mg/mL in 3 cc vials
15. CHEMICAL NAME AND STRUCTURE  
(2-butyl-3-benzofuranyl) [4-(diethylamino)ethoxy]-3,5-diodophenyl]methanone hydrochloride
16. RECORDS AND REPORTS  
None.
17. COMMENTS  
This application was tentatively approved. The applicant submitted a minor amendment to request for final approval. No updated information submitted with the exception of updated labeling due to changes in the innovator's labeling. Labeling acceptable on 8-1-2002 per A.Vezza.
18. CONCLUSIONS AND RECOMMENDATIONS  
Recommend final approval.
19. REVIEWER: Bita Mirzai-Azarm      DATE COMPLETED: May 29, 2002

**APPEARS THIS WAY  
ON ORIGINAL**

*Chem  
Deficiency*

**Redacted** 3

**Page(s) of trade**

**secret and /or**

**confidential**

**commercial**

**information**

DIVISION REVIEW SUMMARY

ANDA: 75-761

DRUG PRODUCT: Amiodarone Hydrochloride

FIRM: American Pharmaceutical Partners (APP)

DOSAGE FORM: Injection

STRENGTH: 50 mg/mL

CONTAINER: 3 mL fill in a 3 mL vial

CGMP STATEMENT/EIR UPDATE STATUS:

Acceptable dated 5/29/01.

BIO INFORMATION:

Bio-waiver granted dated 3/17/00.

VALIDATION

Method validation result is still pending as of 5/9/01.

STABILITY

Lot number R239-005 was placed in accelerated (40°C/75% RH) and room temperature stability studies in the proposed marketing container configuration. 18 months of updated room temperature stability data is included. The stability data appended are found to conform to the proposed stability specifications. Based upon the stability data submitted, the proposed 15 months expiration period for the finished product is granted.

The proposed marketing container is fully described in the container section of the application.

LABELING

Acceptable dated 4/16/01.

STERILIZATION VALIDATION

Final micro review is acceptable 6/25/01

SIZE OF BIO/STABILITY BATCHES

Amiodarone Hydrochloride is ~~\_\_\_\_\_~~ DMF ~~\_\_\_\_\_~~ was reviewed and found to be adequate on 3/29/01.

A ~~\_\_\_\_\_~~ demonstration batch was manufactured. A total of ~~\_\_\_\_\_~~ were filled.

PROPOSED PRODUCTION BATCH

BBR for the intended production batch size of ~~\_\_\_\_\_~~ for a total of ~~\_\_\_\_\_~~ is included.

**Redacted** 2

**Page(s) of trade**

**secret and /or**

**confidential**

**commercial**

**information**